MX2022013861A - Nuevos inhibidores macrociclicos de la quinasa de lrrk2. - Google Patents
Nuevos inhibidores macrociclicos de la quinasa de lrrk2.Info
- Publication number
- MX2022013861A MX2022013861A MX2022013861A MX2022013861A MX2022013861A MX 2022013861 A MX2022013861 A MX 2022013861A MX 2022013861 A MX2022013861 A MX 2022013861A MX 2022013861 A MX2022013861 A MX 2022013861A MX 2022013861 A MX2022013861 A MX 2022013861A
- Authority
- MX
- Mexico
- Prior art keywords
- kinase inhibitors
- lrrk2 kinase
- new macrocyclic
- macrocyclic lrrk2
- new
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Compuestos de la fórmula (I): (ver Fórmula) en donde R, X1, X2, X3, Z1, Z2, Z3, A y Ra son como se han definido en la descripción.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20315236 | 2020-05-06 | ||
| EP21305112 | 2021-01-28 | ||
| PCT/EP2021/061827 WO2021224320A1 (en) | 2020-05-06 | 2021-05-05 | New macrocyclic lrrk2 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013861A true MX2022013861A (es) | 2023-02-22 |
Family
ID=75746649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013861A MX2022013861A (es) | 2020-05-06 | 2021-05-05 | Nuevos inhibidores macrociclicos de la quinasa de lrrk2. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230357269A1 (es) |
| EP (1) | EP4146658A1 (es) |
| JP (1) | JP2023523863A (es) |
| KR (1) | KR20230006560A (es) |
| CN (1) | CN115996932A (es) |
| AU (1) | AU2021267691A1 (es) |
| BR (1) | BR112022022511A2 (es) |
| CA (1) | CA3182162A1 (es) |
| CL (1) | CL2022003070A1 (es) |
| CO (1) | CO2022015871A2 (es) |
| CR (1) | CR20220561A (es) |
| DO (1) | DOP2022000242A (es) |
| IL (1) | IL297867A (es) |
| MX (1) | MX2022013861A (es) |
| PE (1) | PE20230612A1 (es) |
| TW (1) | TW202208379A (es) |
| UY (1) | UY39199A (es) |
| WO (1) | WO2021224320A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022239815A1 (en) * | 2021-03-18 | 2023-09-21 | Les Laboratoires Servier | Macrocyclic lrrk2 kinase inhibitors |
| CN117425660A (zh) * | 2022-05-18 | 2024-01-19 | 上海翊石医药科技有限公司 | 一种芳杂环类化合物及其中间体、药物组合物和用途 |
| WO2023240140A1 (en) * | 2022-06-08 | 2023-12-14 | Blossomhill Therapeutics, Inc. | Indazole macrocycles and their use |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014007654A8 (pt) * | 2011-09-30 | 2018-06-12 | Ipsen Pharma | Inibidores de lrrk2 quinase macrocíclicos. |
| EP3035800B1 (en) * | 2013-08-22 | 2019-10-09 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| SG11201701936WA (en) | 2014-09-17 | 2017-04-27 | Oncodesign Sa | Macrocyclic lrrk2 kinase inhibitors |
| WO2018006931A1 (en) | 2016-07-04 | 2018-01-11 | Telefonaktiebolaget Lm Ericsson (Publ) | Pipelined analog-to-digital converter |
| CA3049820A1 (en) | 2017-01-25 | 2018-08-02 | Glaxosmithkline Intellectual Property Development Limited | Compounds for inhibiting lrrk2 kinase activity |
| US11208412B2 (en) | 2017-02-22 | 2021-12-28 | Daegu-Gyeongbuk Medical Innovation Foundation | Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease |
| BR112019018688A2 (pt) | 2017-03-10 | 2020-04-07 | Pfizer | derivados de imidazo[4,5-c] quinolina como inibidores de lrrk2 |
| US20200157081A1 (en) | 2017-05-24 | 2020-05-21 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| TW201920197A (zh) | 2017-07-14 | 2019-06-01 | 英商葛蘭素史克智慧財產發展有限公司 | 化合物 |
| WO2019074809A1 (en) | 2017-10-11 | 2019-04-18 | Merck Sharp & Dohme Corp. | INDAZOLYL-SPIRO [2.2] PENTANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF |
| MX2020005866A (es) | 2017-12-05 | 2020-09-09 | Oscotec Inc | Derivado de pirrolo(pirazolo)pirimidina como inhibidor de lrrk2. |
| US20210261553A1 (en) | 2018-05-15 | 2021-08-26 | E-Scape Bio, Inc. | Fused tetrazoles as lrrk2 inhibitors |
| US10759799B2 (en) * | 2018-06-15 | 2020-09-01 | Samumed, Llc | Indazole containing macrocycles and therapeutic uses thereof |
| CA3104676A1 (en) | 2018-06-27 | 2020-01-02 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing lrrk2 expression |
-
2021
- 2021-05-05 CR CR20220561A patent/CR20220561A/es unknown
- 2021-05-05 TW TW110116241A patent/TW202208379A/zh unknown
- 2021-05-05 EP EP21722503.6A patent/EP4146658A1/en active Pending
- 2021-05-05 CA CA3182162A patent/CA3182162A1/en active Pending
- 2021-05-05 PE PE2022002552A patent/PE20230612A1/es unknown
- 2021-05-05 US US17/923,002 patent/US20230357269A1/en active Pending
- 2021-05-05 IL IL297867A patent/IL297867A/en unknown
- 2021-05-05 KR KR1020227042327A patent/KR20230006560A/ko active Search and Examination
- 2021-05-05 CN CN202180044443.9A patent/CN115996932A/zh active Pending
- 2021-05-05 WO PCT/EP2021/061827 patent/WO2021224320A1/en active Application Filing
- 2021-05-05 MX MX2022013861A patent/MX2022013861A/es unknown
- 2021-05-05 JP JP2022567124A patent/JP2023523863A/ja active Pending
- 2021-05-05 AU AU2021267691A patent/AU2021267691A1/en active Pending
- 2021-05-05 BR BR112022022511A patent/BR112022022511A2/pt unknown
- 2021-05-06 UY UY0001039199A patent/UY39199A/es unknown
-
2022
- 2022-11-02 DO DO2022000242A patent/DOP2022000242A/es unknown
- 2022-11-03 CO CONC2022/0015871A patent/CO2022015871A2/es unknown
- 2022-11-04 CL CL2022003070A patent/CL2022003070A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2022003070A1 (es) | 2023-07-07 |
| WO2021224320A1 (en) | 2021-11-11 |
| CR20220561A (es) | 2023-02-17 |
| UY39199A (es) | 2021-11-30 |
| JP2023523863A (ja) | 2023-06-07 |
| CA3182162A1 (en) | 2021-11-11 |
| PE20230612A1 (es) | 2023-04-13 |
| CO2022015871A2 (es) | 2022-12-30 |
| DOP2022000242A (es) | 2023-07-31 |
| IL297867A (en) | 2023-01-01 |
| CN115996932A (zh) | 2023-04-21 |
| KR20230006560A (ko) | 2023-01-10 |
| EP4146658A1 (en) | 2023-03-15 |
| TW202208379A (zh) | 2022-03-01 |
| AU2021267691A1 (en) | 2022-12-08 |
| US20230357269A1 (en) | 2023-11-09 |
| BR112022022511A2 (pt) | 2022-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220561A (es) | Nuevos inhibidores macrocíclicos de la quinasa de lrrk2 | |
| MX2009008506A (es) | Derivados del pirazol como inhibidores de 11-b-hsd1. | |
| TN2019000263A1 (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| WO2017109488A8 (en) | Cyanopyrrolidine derivatives as inhibitors for dubs | |
| MX2009010595A (es) | Derivados de pirrolopirimidina. | |
| PH12018502513A1 (en) | Sulfonamide compound or salt thereof | |
| MY170823A (en) | Protein kinase inhibitors | |
| GEP20207111B (en) | Heteroaryl compounds for kinase inhibition | |
| MX2021008356A (es) | Inhibidores de jak2 y alk2 y metodos para su uso. | |
| GEP20207169B (en) | 3-tetrazolyl-benzene-1,2-disulfonamide derivatives as metallo-beta-lactamase inhibitors | |
| MX2009007302A (es) | Derivados de purina. | |
| RS53451B (en) | INHIBITORI P70 S6 KINAZE | |
| MY148107A (en) | Kinase inhibitor | |
| TN2018000087A1 (en) | New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors | |
| TNSN08191A1 (en) | Kinase inhibitors | |
| MX2022002976A (es) | Inhibidores selectivos de jak1. | |
| MX2009005071A (es) | Compuestos de pirazol y triazol sustituidos como inhibidores de ksp. | |
| MX2022006783A (es) | Nuevos derivados de metilquinazolinona. | |
| WO2020259724A3 (zh) | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 | |
| PH12020550253A1 (en) | Bicyclic compounds for use as rip1 kinase inhibitors | |
| PH12021551251A1 (en) | Heterocyclic compound | |
| NZ592392A (en) | PHENANTHROINDOLIZIDINE COMPOUND AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT | |
| UY39680A (es) | Nuevos inhibidores macrocíclicos de la quinasa de lrrk2 | |
| MX2021013981A (es) | Inhibidores de la cinasa aurora y usos de los mismos. | |
| WO2023141432A3 (en) | Apol1 inhibitors and methods of use |